Ixico PLC (LON:IXI) is in a very strong position to weather the coronavirus pandemic, according to Cenkos.
Clinical trial delays are likely to have a bigger impact in the current year than the one just ended, said the broker, but the strong cash position, order book and remote working should enable it to cope.
Over the mid- to longer-term, a significant opportunity remains for the company, believes Cenkos.
Earlier, the brain and neuroscience data group said that for the six months ended March 31, underlying earnings (EBITDA) were £700,000, up from £100,000 a year ago, while revenues jumped by 33% to £4.6mln.
Looking ahead, IXICO said it ended the period with an order book of £15.3mln, however, this had risen to over £22mln in April following the signing of more contracts.
The company added that existing projects across a range of central nervous system indications provided a backlog of revenue-generating data analysis activity for the near term.
Shares were trading at 71.5p midday on Wednesday.